# A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

> **NCT07249632** · PHASE3 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Myasthenia Gravis, Ocular

## Interventions

- **DRUG:** Telitacicept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07249632
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-13
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-02-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07249632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07249632, "A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07249632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*